Panagora Asset Management
TSHA icon

Panagora Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Panagora Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.02M Buy
590,387
+408,223
+224% +$2.42M 0.01% 491
2026
Q1 		$814K Buy
182,164
+170,590
+1,474% +$793K ﹤0.01% 758
2025
Q4 		$63.7K Buy
+11,574
New +$56.2K ﹤0.01% 1164

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Panagora Asset Management's TSHA Position: Q2 2026 in Review

Panagora Asset Management increased its Taysha Gene Therapies (TSHA) stake by 224% in Q2 2026, buying an estimated $2.42M and bringing the position to 590,387 shares worth $4.02M. The position accounts for 0.01% of the portfolio, ranked #491.

Panagora Asset Management first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Panagora Asset Management held 590,387 shares of Taysha Gene Therapies worth $4.02M as of Q2 2026.
  • Panagora Asset Management bought 408,223 Taysha Gene Therapies shares in Q2 2026, an estimated $2.42M.
  • Taysha Gene Therapies made up 0.01% of Panagora Asset Management's portfolio in Q2 2026, its #491 holding.
  • Panagora Asset Management first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.